Dr. William Abramovits, MD

Dr. Abramovits practices at Dermatology Treatment & Research Center, PA in Dallas, Texas.

Dr. Abramovits' NPI, 1154379188, was assigned on May 4, 2006. Dr. Abramovits graduated from Central University of Venezuela in 1972. Dr. Abramovits' Texas license number on file is H6757.

Dr. Abramovits' primary practice is Dermatology Treatment & Research Center, PA, at 5310 Harvest Hill Rd, Dallas, TX 75230 in Dallas County. The practice phone is (972) 661-2729.

Dr. Abramovits' primary practice is Dermatology Treatment & Research Center, PA in Dallas, Texas. The medical group on file is Bare Dermatology. Dmand AI also links Dr. Abramovits to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abramovits practices. Vendor and product names are available with a free account.

Dermatology is Dr. Abramovits' primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Abramovits is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Abramovits' licenses on file in 2 states: Texas and Oklahoma.

Dmand AI lists acute skin infection, benign or precancerous skin growths, contact dermatitis, corns and calluses, itchy rashes, minor injury to a limb, psoriasis and scalp rash among the conditions Dr. Abramovits treats.

CMS data shows 346 Medicare services from Dr. Abramovits across 6 procedure codes in 2024, for 90 Medicare patients. Medicare paid $19,118 for them. Every service was in an office.

CMS counts 90 Medicare patients who saw Dr. Abramovits in 2024. The largest group is 65 to 74, with 51 patients. 75% of them have high cholesterol, and 69% have high blood pressure. Their average risk score is 0.92, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Abramovits' median patient age at 58, with 43% women.

In 2024, Dr. Abramovits wrote 149 Medicare Part D claims for 56 patients. 81% of them were for generic drugs. CMS names the drug for 38 of them, across 3 drugs with 11 or more claims each, at $1,822 in total drug cost. In 2023, CMS named 37 claims across 3 drugs.

Dr. Abramovits accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 131 procedures of removal of skin lesions by Dr. Abramovits, more than 77% of the clinicians it reports for that procedure.

Dmand AI links 95 papers to Dr. Abramovits, published from 2013 to 2025. 2024 was the busiest year, with 10. The most frequent topics are Administration, Cutaneous, Dermatitis, Atopic and Dermatologic Agents. Dr. Abramovits has published most often in Skinmed. Dr. Abramovits' most frequent co-authors are Aditya Gupta, MD, Brian Berman, MD, PhD and Sady Armada Alpizar, MD.

Dmand AI links Dr. Abramovits to 13 clinical trials, 5 of them phase 2 studies. Conditions studied include Eczema, Dermatitis, Atopic and Psoriasis. Eli Lilly and Company sponsors the most, 6. Open Payments lists research payments to Dr. Abramovits that name 6 trials.

CMS Open Payments shows 2,607 general payments to Dr. Abramovits from 56 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 56% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $115,158. It also lists 44 research payments totaling $87,673 from 2016 to 2024, naming 6 clinical trials.

Dr. Abramovits graduated from Central University of Venezuela in 1972.

Dr. Abramovits is in network with 16 carriers, including Aetna, United Healthcare and Elevance. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.